For nearly half of people diagnosed with lung cancer, immunotherapy can slow the disease but not stop it. Funded through a $4 million joint investment from the Canadian Cancer Society (CCS) and the Weston Family Foundation, a new clinical trial aims to change that.
LUNA-2: LND101 in Unresectable Non-Small Cell Lung Cancer: A Randomized Phase II Trial
Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated AML: A myeloMATCH Substudy
Autologous Stem Cell Transplant in Peripheral T Cell Lymphoma that Achieved a First Complete Remission (CR1) Following Induction Therapy (PTCL-STAT)
Lanreotide for the Prevention of Postoperative Pancreatic Fistula
A new survey study SC32S, collecting sociodemographic data from clinical trial participants, has now opened across Canada. This study will help researchers understand the feasibility of using a survey to gather information about trial participants’ backgrounds and everyday lives.
Phase II Trial of ASTX727 and Venetoclax Compared with ASTX727, Venetoclax, and Enasidenib for New Diagnosed Older Adults with IDH2 Mutant AML - A myeloMATCH Substudy
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
Investigating Precision Medicine in the Adjuvant setting: a phase III Clinical Trial in Biliary tract cancer (SAFIR IMPACT BTC)
Induction Pembrolizumab and Chemotherapy Followed by Chemoradiation and Pembrolizumab vs Chemoradiation and Pembrolizumab Both Followed by Pembrolizumab for High Risk Locally Advanced Cervical Cancer
RAINBO-ORANGE: Treatment of Endometrial Cancer Based On Molecular Features
MiRNA371-Guided MAnagement in Testicular germ cell tumors- MAGMA GCT
The next CCTG Clinical Research Associate (CRA) Lunch and Learn training session will be on Wednesday Jun 24th, 2025, at 12 pm ET, covering the top
In recognition of the critical role played by the CCTG throughout her professional career, Dr. Frances Shepherd has provided support for an annual travel award to recognize excellence in clinical trials and translational research within CCTG research projects.
RIPPLE Reminders & Upcoming Additions
The Roster Interface Program & Participants List Environment, commonly known as RIPPLE is a single electronic system which permits:
The next Clinical Research Associate (CRA) Lunch and Learn session: CCTG Correlative Samples - TTDR, LETTUCE and shipping will be held on Wednesday, Nov 25th, 2026, at 12 pm ET. This session will include an overview of the TTDR, kit requests, waybill requests, shipping samples to the TTDR, as well as a LETTUCE demo.
While a fully executed and signed informed consent form (ICF) is an important component of the consent record, the signature alone does not demonstrate the consent process. Clinical trial teams must be able to demonstrate that participants received appropriate information, had the opportunity to ask questions of the investigator and/or delegate and consider participation, understood the information relevant to their decision, and made a voluntary decision before any trial-related procedures were performed.
November is Neuroendocrine Tumor (NET) Awareness Month, where we come together to engage with the public and medical community about neuroendocrine cancers.
The Commonwealth Neuroendocrine Tumour Collaboration Annual Research workshop is a two-day forum for collaboration, knowledge sharing and strategic planning. The program will include research and clinical trial updates, new concepts and proposal presentations, collaborative workshopping, and much more.
Establishment of harmonized international reference ranges for plasma estradiol concentrations in postmenopausal women
